<DOC>
	<DOCNO>NCT01753401</DOCNO>
	<brief_summary>This Phase 4 study perform examine effect Acthar indicate use treatment SLE . This study enroll patient steroid-dependent , persistently active SLE arthritic and/or cutaneous involvement . The study involve two phase : double-blind phase , provide placebo-controlled safety , efficacy , pharmacodynamic data , optional open-label phase , examine prolonged effect Acthar maintenance .</brief_summary>
	<brief_title>Acthar Treatment Systemic Lupus Erythematosus Patients With History Persistently Active Disease</brief_title>
	<detailed_description>The first phase study 8-week randomize , double-blind , placebo-controlled , parallel-group add-on pilot study explore efficacy , safety , pharmacodynamics Acthar SLE patient history persistently active disease arthritic and/or cutaneous involvement despite standard care , include chronic/stable prednisone use minimum 4 week prior screen . Patients randomize one four possible treatment group ( Acthar [ low dose ( 40 U [ 0.5 mL ] ) high dose ( 80 U [ 1.0 mL ] ) ] equivalent volume Placebo [ low high 'dose ' ] ) 2:1:2:1 ratio ( Acthar : Placebo : Acthar : Placebo ) . In Weeks 1-4 , patient administer study medication via subcutaneous ( SC ) injection 0.5 mL daily 1.0 mL every day base randomization . In Weeks 5-8 , patient taper study medication . Patients continue stable steroid regimen phase study . After completion Week 8 double-blind phase , patient may choose participate optional open-label phase receive Acthar maintenance regimen 44 week . The initial Acthar regimen assign base study medication regimen patient receive completion double-blind phase ( Visit 6 , Week 8 ) . Acthar regimen may adjust base Investigator 's judgment goal achieve stable Acthar regimen later Week 28 . Once stable Acthar regimen achieve , Investigator consider taper steroid regimen low daily dose completely discontinue .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Male female ≥ 18 year age screen able provide inform consent Diagnosis SLE accord American College Rheumatology revise criterion ( fulfil ≥ 4 criterion ) Active SLE arthritic and/or cutaneous involvement demonstrate SELENASLEDAI score ≥ 2 ( clinical manifestation must include rash and/or arthritis ) Moderate severe rash and/or arthritis demonstrate BILAG score A B mucocutaneous and/or musculoskeletal body system Documented history autoantibody least one following : antidsDNA , antiSmith , anticardiolipin Documented history positive antinuclear antibody ( ANA ) Currently stable dose prednisone ( 7.5 30 mg/day prednisone equivalent within 4 week prior screen ) . The prednisone regimen must remain stable doubleblind phase stable Acthar regimen attain openlabel phase . Patients recent history ( ≤ 2 month prior screen ) start prednisone ( equivalent ) use Patients active nephritis define serum creatinine &gt; 2.5 mg/dL protein creatinine ratio ( PCR ) &gt; 1.5 g/g , patient require hemodialysis within 3 month prior screen Active central nervous system ( CNS ) lupus ( include seizure , psychosis , organic brain syndrome , cerebrovascular accident , cerebritis , CNS vasculitis ) , require therapeutic intervention within 3 month prior screen Type 1 type 2 diabetes mellitus ( history gestational diabetes mellitus exclusion ) , patient currently take hypoglycemic medication History use certain medication prior screen : 1. oral prednisone ( equivalent ) &gt; 30 mg/day , steroid injection , cyclosporine , nonbiologic investigational drug within 3 month prior screen 2 . IVIg plasmapheresis within 4 month prior screen 3. cyclophosphamide within 6 month prior screen ; and/or 4 . Bcell target therapy , abatacept , biologic investigational agent within 12 month prior screen Contraindication per Acthar Prescribing Information : scleroderma , osteoporosis , systemic fungal infection , ocular herpes simplex , recent surgery , history presence peptic ulcer , congestive heart failure , uncontrolled hypertension , primary adrenocortical insufficiency , adrenal cortical hyperfunction 1 . For purpose study , osteoporosis define evidence vertebral long bone fracture vertebral Tscore &gt; 2.0 2 . For purpose study , history peptic ulcer define ≤ 6 month prior screen 3 . For purpose study , congestive heart failure define New York Heart Association Functional Class IIIIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
</DOC>